Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Social media can help compare the effectiveness and safety of new arthritis medications.

ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.

DA-9401 helps protect rat testis from finasteride damage.

5α-reductase inhibitors may increase the risk of depression and suicidal thoughts.

Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.

Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.

Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.

Baricitinib may not always prevent relapse in alopecia areata.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.

Promising cancer treatments were found, but the manufacturer closed.

Scientists found new, better-working inhibitors for a hormone-related enzyme.

Apremilast did not work for treating severe alopecia areata.

Manipulating 5α-reductase type 2 can affect liver fat production and glucocorticoid effects.

Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.

The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Baricitinib is effective in promoting hair growth in severe alopecia areata.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

Targeting androgen receptor signaling may improve acute myeloid leukemia treatment.

JAK inhibitors can effectively reverse hair loss in people with alopecia areata.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Epristeride's metabolism in zebrafish helps improve doping detection methods.

PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.

Upadacitinib effectively treated alopecia areata when other treatments failed.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.